Analysts Set Immuneering Co. (NASDAQ:IMRX) Target Price at $12.20

Immuneering Co. (NASDAQ:IMRX - Get Free Report) has been assigned an average rating of "Hold" from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $12.20.

Several analysts have weighed in on the company. Morgan Stanley cut Immuneering from an "equal weight" rating to an "underweight" rating in a research report on Friday, December 13th. Needham & Company LLC restated a "buy" rating and set a $12.00 price target on shares of Immuneering in a research report on Thursday, February 6th. Finally, Chardan Capital reiterated a "buy" rating and issued a $13.00 price objective on shares of Immuneering in a report on Wednesday, January 8th.

Immuneering Stock Down 10.3 %

Shares of NASDAQ:IMRX traded down $0.17 on Friday, hitting $1.48. The company had a trading volume of 555,843 shares, compared to its average volume of 2,580,407. Immuneering has a 1 year low of $1.00 and a 1 year high of $7.68. The firm's 50-day simple moving average is $1.99 and its two-hundred day simple moving average is $1.95. The firm has a market capitalization of $45.95 million, a price-to-earnings ratio of -0.75 and a beta of -0.36.

Remove Ads

Institutional Investors Weigh In On Immuneering

Several hedge funds have recently added to or reduced their stakes in IMRX. HighTower Advisors LLC grew its position in Immuneering by 21.4% during the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company's stock valued at $132,000 after purchasing an additional 9,400 shares during the last quarter. Corsair Capital Management L.P. bought a new stake in shares of Immuneering during the third quarter valued at approximately $25,000. Southport Management L.L.C. raised its holdings in Immuneering by 4.9% in the 4th quarter. Southport Management L.L.C. now owns 215,000 shares of the company's stock worth $473,000 after acquiring an additional 10,000 shares during the last quarter. Two Sigma Investments LP lifted its position in Immuneering by 25.0% in the 4th quarter. Two Sigma Investments LP now owns 50,557 shares of the company's stock valued at $111,000 after acquiring an additional 10,126 shares in the last quarter. Finally, Tang Capital Management LLC purchased a new stake in Immuneering during the 4th quarter valued at $27,000. 67.65% of the stock is owned by institutional investors.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.